Cadex Genomics, a newly funded company based on technology developed in Louisiana, recently announced the launch of a clinical study at Rocky Mountain Cancer Center. The company had recently raised $1.5 Million to cover operations and clinical studies to bring its initial product, Alibrex, to market. Veteran entrepreneur and Alibrex inventor Sudhir Sinha has joined the company as the Chief Scientific Officer. Alibrex is a blood-based assay that indicates when a patient with a stage IV solid tumor cancer is not responding to therapy within two weeks after treatment commences. Learn more about Cadex and its products at https://www.cadexgenomics.com.